- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06064149
Utvärdering av kardiovaskulär risk hos män med prostatacancerstudie (CARE-PC) Pilotförstudie
Utvärdering av kardiovaskulär risk hos män med prostatacancerstudie (CARE-PC): Inledande pilotstudie för att bedöma patientmedvetenhet och riskreducering
The overarching goal of this trial is to develop mechanisms to improve cardiovascular care among such prostate cancer patients receiving ADT by increasing patient awareness of individualized cardiovascular risk estimates and mitigation opportunities. Patients will be given access to a web-based quality improvement tool to educate patients of cardiovascular risks in prostate cancer and to inform them of their individualized, estimated cardiovascular risk and guideline-based risk mitigation recommendations.
The study will assess the feasibility of this web-based application as a cardiovascular education tool for patients with prostate cancer.
The study will also evaluate if completion of the web-based tool improves cardiovascular care access and risk mitigation for patients with prostate cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Abramson Cancer Center of the University of Pennsylvania
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of ADT
- Patients must be able to read and understand English.
Exclusion Criteria: n/a
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Men With Prostate Cancer Planned for Receiving ADT
Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of systemic androgen deprivation therapy (ADT). |
The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
CARE-PC Web-Based Application Completion Rate
Tidsram: 18 months
|
Completion rate measured as the proportion of participants successfully completing the web-based application out of the total number of subjects approached. |
18 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Patient acceptance and perception of the web-based application
Tidsram: 18 months
|
Acceptance/perception measured by brief embedded survey following participation in the web-based application |
18 months
|
|
Percent accuracy of patient-derived CV- and prostate cancer-related data elements
Tidsram: 18 months
|
Accuracy assessed through parallel medical chart review by cardiology and oncology clinicians |
18 months
|
|
Prevalence of CV risk factors/disease at the time of CARE-PC web-based application participation
Tidsram: 18 months
|
Prevalence assessed through parallel medical chart review by cardiology and oncology clinicians |
18 months
|
|
Proportion of participants with current cardiologist involvement in CV care at the time of web-based application participation
Tidsram: 18 months
|
Patient reported cardiologist involvement via CARE-PC application at time of application survey completion |
18 months
|
|
Proportion of participants engaging in CV care within 6 months of CARE-PC web application participation
Tidsram: 18 months
|
CV care engagement assessed through medical chart review by investigators within 6 months post-application survey completion |
18 months
|
|
Proportion of participants having changes in CV risk-reducing medications within 6 months of CARE-PC application participation.
Tidsram: 18 months
|
Proportion of participants having changes in CV risk-reducing medications assessed through parallel medical chart review by cardiology and oncology clinicians within 6 months post-application survey completion |
18 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Vivek Narayan, MD, University of Pennsylvania
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- UPCC 07823
- 853844 (Annan identifierare: University of Pennsylvania IRB)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .